Dr Lennard Lee recognised as one of 21 outstanding young physicians below the age of 40
27 October 2022
The Departmental academic clinical lecturer receives this recognition and was invited to take part in the InterAcademy Partnership Young Physician Leaders Programme 2022 in Berlin.
Dr Lennard Lee was nominated by The Academy of Medical Sciences for safeguarding cancer and immunocompromised patients during the coronavirus pandemic and innovations in cancer diagnostics. As part of selection into this group, Lennard met with other young physician leaders from across the world in Berlin in October to harnesses the expertise of the world’s leading scientific minds to advance sound policies, improve public health and promote excellence in science education. He also was given the opportunity to present at the World Health Summit in Berlin a 'global pact to protect those with cancer and the immunocompromised'
Dr Peter McGrath, awarding panel from the global InterAcademy Partnership (IAP) said: Lennard is a great candidate and an excellent example of young physician leadership. We are delighted in getting him to share his contribution and insights at this international event in 2022"
DR LENNARD LEE'S BLOG ABOUT THE EVENT
The Academy of Medical Sciences UK and the global InterAcademy Partnership (IAP) has generously given me an accolade for work done at the Department of Oncology in the last 2 years in my role of Academic Clinical Lecturer.
However, I think it is important to look beyond the headlines. It is great in this blog to 'lift the bonnet' on what the accolade was awarded for. Young physician researcher leaders stand on the shoulders of giants, and there are so many visionaries and giants here in the Department of Oncology. Without them, this award wouldn't have been possible.
The award was given for two major research initiatives which have arisen from Oxford.
- Population scale research, using massive datasets is a strength of the Department of oncology. We turned this technology to the pandemic response. We comprehensively measured vaccine effectiveness in nearly half a million cancer patients in the UK. This is the largest global COVID cancer dataset and identified the need for ongoing coronavirus boosters in the cancer population. All of us are very proud of this "Pace-setting" programme and demonstrating terms of what was possible with our UK health datasets
- Hyper-accelerated trials are a new innovation in terms of trial design. They are characterised by speed and are based on learnings from other Oxford successes like the RECOVERY study or our vaccine studies. I was delighted in being acknowledged by the IAP in delivering 5 of these studies since 2020. I have seen these hyper-accelerated trials in progress and leading on many of them. They are providing much more rapid patient benefit and this is very exciting for the future.
The work in population-scale research and hyper-accelerated trials are two key research concepts that I am delighted to have helped achieve with the department of Oncology. Oxford remains are at the vanguard of these research areas. There is so much talent in the Department to drive these new concepts and areas. They have the potential to transform cancer care in the decades ahead.
I am grateful for all my collaborators and the talented researchers in the department. OUCAGS deserve thanks for helping make space between our Oxford giants and Mark Middleton for this fantastic environment for success at Oxford for young research leaders.